Paper Details

  1. Home
  2. Paper Details

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

Author: BanerjiLolita, CallahanLinda, CatleyLaurie, DellaGattaJamie L, FabbroDoriano, GriffinJames D, Hall-MeyersElizabeth, JiangJingrui, KungAndrew L, ManleyPaul W, MestanJuergen, MorenoDaisy, RayArghya, WeisbergEllen, WrightRenee D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that the combination of imatinib and nilotinib may be more effective in treating chronic myelogenous leukemia (CML) than either drug alone. The combination was at least additive in antileukemic activity.
Paper Details　
Original Abstract of the Article :
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR-ABL inhibitor, nilotinib (AMN107), is significantly more potent against BCR-ABL than imatinib, and is active against many imat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1801049/

データ提供：米国国立医学図書館（NLM）

Combating Cancer with a Double-Headed Strategy

The battle against [cancer] is a complex and ever-evolving landscape. This preclinical study explores the potential of combining two targeted therapies, nilotinib and imatinib, to combat drug resistance in chronic myelogenous leukemia (CML). Researchers have demonstrated the additive or synergistic cytotoxic effects of this combination in various BCR-ABL+ cell lines, including those resistant to imatinib. Their findings suggest that this dual approach could be a powerful weapon in the fight against drug-resistant CML.

A Two-Pronged Attack: Combining Therapies to Overcome Resistance

This study highlights the potential of combining therapies to overcome drug resistance. It’s like a desert traveler using a combination of a camel and a map to navigate the challenging terrain. This dual approach could be crucial in the battle against drug-resistant cancers.

Hope on the Horizon: A Promising Strategy for Cancer Treatment

This research provides hope for patients with drug-resistant CML, suggesting that a combination therapy could be a viable and effective treatment option. It's like finding a hidden spring in the desert; offering a source of hope and renewal.

Dr.Camel's Conclusion

This study lays the groundwork for clinical trials investigating the combination of nilotinib and imatinib for CML. It highlights the importance of innovative strategies and personalized treatment approaches in the ongoing fight against cancer. This research is like a beacon in the desert, guiding us towards a brighter future for cancer patients.

Date :
  1. Date Completed 2007-03-20
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

17068153

DOI: Digital Object Identifier

PMC1801049

Related Literature

Article Analysis
・Effects of nilotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.